Vemurafenib
Back to searchMolecule Structure
Scientific Name
Vemurafenib
Description of the Drug
Vemurafenib is a kinase inhibitor used to treat patients with Erdheim-Chester Disease who have the BRAF V600 mutation, and melanoma in patients who have the BRAF V600E mutation.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08881
http://www.drugbank.ca/drugs/DB08881
Brand Name(s)
Zelboraf
Company Owner(s)
Hoffmann La Roche Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Serine/threonine-protein kinase B-raf | SINGLE PROTEIN | INHIBITOR | CHEMBL5145 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL298931 | |
| PharmGKB | PA165946873 | |
| Human Metabolome Database | HMDB0259779 | |
| DrugBank | DB08881 | |
| PubChem: Thomson Pharma | 99207986 | |
| PubChem | 42611257 | |
| Mcule | MCULE-7244406627 | |
| LINCS | LSM-1068 | |
| Nikkaji | J2.870.988I | |
| PDBe | 032 | |
| BindingDB | 50396483 | |
| EPA CompTox Dashboard | DTXSID50238710 | |
| DrugCentral | 4185 | |
| ChemicalBook | CB22515128 | CB02550000 |
| Guide to Pharmacology | 5893 | |
| rxnorm | VEMURAFENIB | ZELBORAF |
| PubChem: Drugs of the Future | 123055406 | |
| ChEBI | 63637 | |
| ZINC | ZINC000052509366 |
